Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gaboxadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 12/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 7/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gaboxadol SCHEMBL5533785 | 1.00 | CHRM3 (0.46) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL3983776 | 0.98 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL3979055 | 0.98 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL3983708 | 0.98 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL567225 | 0.98 | CHRM3 (0.49) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL23851948 | 0.98 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL1403323 | 0.98 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL3981267 | 0.98 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL3980688 | 0.98 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 | |
| Gaboxadol SCHEMBL1403469 | 0.98 | CHRM3 (0.45) | CHRM3HTR2CCHRM5CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4010 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114008013-B | Treatment of CNS disorders with sleep disorders | 哥本哈根大学 | 2026-05-15 | — | — | CN | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| CN-122005553-A | Application of gaboxadol or pharmaceutically acceptable salt thereof in preparation of medicine for treating liver fibrosis diseases | 首都医科大学 | 2026-05-12 | — | — | CN | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20250375429-A1 | OBLIGATE PAIRING OF ORTHOSTERIC AND NON-ORTHOSTERIC GABA LIGANDS IN PHARMACEUTICAL FORMULATIONS | SMARTER NOT HARDER, INC. (US) | 2025-12-11 | — | — | US | claimed |
| US-20250235554-A1 | METHODS FOR IMPROVING ADENO-ASSOCIATED VIRUS (AAV) DELIVERY | NOVARTIS AG (CH) | 2025-07-24 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-120025976-A | Method for differentiating hematopoietic stem/progenitor cells into granulocytes | 苏州血霁生物科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| US-20250163379-A1 | METHOD FOR DIFFERENTIATING HEMATOPOIETIC STEM/PROGENITOR CELLS INTO NK CELLS | HEMACELL BIOTECHNOLOGY INC. (CN) | 2025-05-22 | — | — | US | claimed |
| EP-4541420-A2 | METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH GABOXADOL | Ovid Therapeutics Inc. (US) | 2025-04-23 | — | — | EP | claimed |
| EP-0789567-A1 | A METHOD FOR TREATING VASCULAR HEADACHES | THE GENERAL HOSPITAL CORPORATION (US) | 1997-08-20 | — | — | EP | claimed |
| WO-1997002813-A1 | NON-ALLOSTERIC GABAA AGONISTS FOR TREATING SLEEP DISORDERS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1997-01-30 | — | — | WO | claimed |
| WO-1996015782-A1 | A METHOD FOR TREATING VASCULAR HEADACHES | THE GENERAL HOSPITAL CORPORATION (US) | 1996-05-30 | — | — | WO | claimed |
| EP-0630240-A1 | METHOD FOR REDUCING INTRAOCULAR PRESSURE IN THE MAMMALIAN EYE BY ADMINISTRATION OF GAMMA AMINOBUTYRIC ACID (GABA) AGONISTS | ALLERGAN, INC. (US) | 1994-12-28 | — | — | EP | claimed |
| WO-1993018762-A2 | METHOD FOR REDUCING INTRAOCULAR PRESSURE IN THE MAMMALIAN EYE BY ADMINISTRATION OF GAMMA AMINOBUTYRIC ACID (GABA) AGONISTS | ALLERGAN, INC. (US) | 1993-09-30 | — | — | WO | claimed |
| US-4362731-A | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof | SANDOZ LTD. (CH) | 1982-12-07 | — | — | US | claimed |
| US-4315934-A | 4,5,6,7-TETRAHYDROISDOXAZOLO(5,4-C) PYRIDIN-3-OL ANALGESIC | SANDOZ LTD. (CH) | 1982-02-16 | — | — | US | claimed |
| EP-0000338-B1 | ISOXAZOLO(5,4-C)PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | H.Lundbeck & Co., A/S (DK) | 1981-11-25 | — | — | EP | claimed |
| US-4278676-A | NERVOUS SYSTEM DISORDERS, CYCLIZATION, HYDROLYSIS | H. LUNDBECK & CO. A/S (DK) | 1981-07-14 | — | — | US | claimed |
| EP-0000338-A2 | Isoxazolo(5,4-c)pyridine derivatives, their preparation and pharmaceutical compositions containing them | H.Lundbeck & Co., A/S (DK) | 1979-01-24 | — | — | EP | claimed |